Targeted oncology SBH Sciences specializes in anti-cancer and inflammation drug development and maintains a large in vitro oncology lead screening capability with over 370 human cancer cell lines, presenting a clear opportunity to offer preclinical CRO services for oncology programs at various stages.

Incubator partnerships With an incubator-model approach for early-stage biotechnology companies, SBH Sciences is well positioned to engage startups needing early translational services, cytokine and enzyme production, and cell-based discovery support.

Biomarker expertise The extensive biomarker platform including 330 cytokine bioassays and advanced platforms (ELISA, Luminex, Western blot, ELLA, MSD, HTRF, Alpha-Lisa, FACS, qRT-PCR) enables comprehensive biomarker discovery and validation for inflammatory and cancer pathways.

NAFLD/NASH focus Recent development of a hepatocyte-isolated extracellular vesicle platform targeting RNA and protein biomarkers related to NAFLD/NASH suggests a potential expansion area for liver disease programs and associated analytical services.

Revenue scale With estimated annual revenue in the $10M–$25M range and a strong track record of on-time delivery and quality, SBH Sciences can be positioned as a reliable mid-market CRO for mid-to-late stage preclinical studies, potentially expanding to larger collaborations with similar firms.